Are we on the Titanic?

Quote

anonymous

Guest
With all of the hype around this product and no clinical evidence, now that we are out to sea-
It appears that our leader has been thrown overboard, a new captain is at the helm, and there is still no access to this product through the reimbursement channels. We do not need to repeat history, there were not enough life boats to save the people. Will someone please tell Frost that the coast guard will not rescue this drug without navigating the proper reimbursement channels.
 






anonymous said:
With all of the hype around this product and no clinical evidence, now that we are out to sea-
It appears that our leader has been thrown overboard, a new captain is at the helm, and there is still no access to this product through the reimbursement channels. We do not need to repeat history, there were not enough life boats to save the people. Will someone please tell Frost that the coast guard will not rescue this drug without navigating the proper reimbursement channels.[

And the sales force is in steerage with the gates locked.
Click to expand...
 












OPKO Announces U.S. Launch of RAYALDEE™

November 23, 2016

MIAMI, Nov. 23, 2016 (GLOBE NEWSWIRE) --OPKO Health, Inc. (Nasdaq:OPK), today announced that it will commence shipments of RAYALDEE™ (calcifediol) extended-release capsules to distributors in the United States on Tuesday, November 29, 2016. The product will be available nationwide at retail pharmacies as early as Wednesday, November 30, 2016.

The U.S. launch of RAYALDEE follows the successful introduction of the product to thousands of nephrologists attending the American Society of Nephrology (ASN) Kidney Week Meeting last week in Chicago. RAYALDEE was approved by the U.S. Food and Drug Administration (FDA) on June 17, 2016.

"The RAYALDEE launch represents a major milestone for OPKO," commented Phillip Frost, M.D., CEO and Chairman of OPKO. "RAYALDEE is the first product developed by OPKO to be commercialized by our own marketing and sales teams, and represents an important contribution to the care of patients with chronic kidney disease. Based on the highly positive reception of RAYALDEE by nephrologists attending the recent ASN meeting, we believe that RAYALDEE will become a mainstay in the armamentarium of treatment options available for kidney disease patients."
 










































Top Bottom
Back
Quote